Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients

Thrombosis and Haemostasis

Volumn 97, Issue 3, 2007, Pages 487-492

  Zafar, M Urooj ^a   Farkouh, Michael E ^a,b   Osende, Julio ^a   Shimbo, Daichi ^a   Palencia, Stella ^a   Crook, Julia ^c   Leadley, Robert ^d   Fuster, Valentin ^a   Chesebro, James H ^b  

^a Zena and Michael A Wiener Cardiovascular Institute   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d PFIZER INC   (United States)

Author keywords

Coagulation; Coronary disease; Myocardial infarction; Platelets; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 10; N [2 (5 AMIDINO 2 HYDROXYPHENOXY) 3,5 DIFLUORO 6 [3 (1 METHYL 1H 2 IMIDAZOLIN 2 YL)PHENOXY] 4 PYRIDINYL] N METHYLGLYCINE; PLACEBO; THROMBOPLASTIN;

ABSENCE OF SIDE EFFECTS; ACUTE CORONARY SYNDROME; ADULT; AGED; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BOLUS INJECTION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART INFARCTION; HEMOSTASIS; HUMAN; LOW DRUG DOSE; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SIDE EFFECT;

AMIDINES; ANIMALS; AORTA; BLOOD COAGULATION; CORONARY ARTERIOSCLEROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FACTOR XA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PERFUSION; PROTHROMBIN TIME; PYRIDINES; SWINE; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33947302258     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-04-0188     Document Type: Article

References (35)

1. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326: 242-250.
2. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992; 326: 310-318.
3. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-671.
4. Rauch U, Osende JI, Fuster V, et al. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med 2001; 134: 224-238.
5. Nelken NA, Soifer SJ, O'Keefe J, et al. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 1992; 90: 1614-1621.
6. Wysokinski W, McBane R, Chesebro JH, et al. Reversibility of platelet thrombosis in vivo. Quantitative analysis in porcine carotid arteries. Thromb Haemost 1996; 76: 1108-1113.
7. Oler A, Whooley MA, Oler J, et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. J Am Med Assoc 1996; 276: 811-815.
8. Eikelboom JW, Anand SS, Malmberg K, et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000; 355: 1936-1942.
9. Orvim U, Barstad RM, Vlasuk GP, et al. Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/ factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis. Arterioscler Thromb Vasc Biol 1995; 15: 2188-2194.
10. McClanahan TB, Hicks GW, Morrison AL, et al. The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis. Eur J Pharmacol 2001; 432: 187-194.
11. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347: 969-974.
12. Brouwer MA, van den Bergh PJ, Aengevaeren WR, et al. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrenolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. Circulation 2002; 106: 659-665.
13. van Es RF, Jonker JJ, Verheugt FW, et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002; 360: 109-113.
14. Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-1574.
15. Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991; 324: 1865-1875.
16. Waxman L, Smith DE, Arcuri KE, et al. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 1990; 248: 593-6.
17. Nutt EM, Jain D, Lenny AB, et al. Purification and characterization of recombinant antistasin: a leech-derived inhibitor of coagulation factor Xa. Arch Biochem Biophys 1991; 285: 37-44.
18. Hara T, Yokoyama A, Tanabe K, et al. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb Haemost 1995; 74: 635-639.
19. Shimbo D, Osende J, Chen J, et al. Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin. Thromb Haemost 2002; 88: 733-738.
20. Hauptmann J, Sturzebecher J. Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. Thromb Res 1999; 93: 203-241.
21. Sato K, Kawasaki T, Hisamichi N, et al. Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time. Br J Pharmacol 1998; 123: 92-96.
22. Abendschein DR, Baum PK, Verhallen P, et al. A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs. J Pharmacol Exp Ther 2001; 296: 567-572.
23. Green D, Hirsh J, Heit J, et al. Low molecular weight heparin: a critical analysis of clinical trials. Pharmacol Rev 1994; 46: 89-109.
24. Post JM, Sullivan ME, Abendschein D, et al. Human in vitro pharmacodynamic profile of the selective factor Xa inhibitor ZK-807834 (CI-1031). Thromb Res 2002; 105: 347-352.
25. Karnicki K, McBane RD, 2nd, Miller R, et al. Inhibition and reversal of platelet-rich arterial thrombus in vivo: direct vs. indirect factor Xa inhibition. J Thromb Haemost 2004; 2: 2162-2169.
26. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-599.
27. Badimon JJ, Meyer B, Feigen LP, et al. Thrombosis triggered by severe arterial lesions is inhibited by oral administration of a glycoprotein IIb/IIIa antagonist. Eur J Clin Invest 1997; 27: 568-574.
28. Dangas G, Badimon JJ, Smith DA, et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 1999; 33: 1294-1304.
29. Badimon JJ, Lettino M, Toschi V, et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999; 99: 1780-1787.
30. Badimon L, Badimon JJ, Galvez A, et al. Influence of arterial damage and wall shear rate on platelet deposition. Ex vivo study in a swine model. Arteriosclerosis 1986; 6: 312-320.
31. Reverter JC, Beguin S, Kessels H, et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest 1996; 98: 863-874.
32. Hayes R, Chesebro JH, Fuster V, et al. Antithrombotic effects of abciximab. Am J Cardiol 2000; 85: 1167-1172.
33. Helft G, Osende JI, Worthley SG, et al. Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin. Arterioscler Thromb Vasc Biol 2000; 20: 2316-2321.
34. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
35. Fuster V, Badimon JJ, Chesebro JH. Atherothrombosis: mechanisms and clinical therapeutic approaches. Vasc Med 1998; 3: 231-239.